10-Q: Nika Pharmaceuticals Reports Q3 2024 Results, Navigates Complex Restructuring

Nika Pharmaceuticals reported its Q3 2024 results, showing a net loss and ongoing efforts to establish its pharmaceutical manufacturing capabilities.

Summary

• Nika Pharmaceuticals, Inc. filed its Form 10-Q for the quarter ended September 30, 2024, revealing a net loss of $8,367 for the quarter and $83,339 for the nine-month period.
• The company's cash balance significantly decreased from $19,596 at the end of 2023 to $1,386 as of September 30, 2024.
• The company has been undergoing significant restructuring, including a merger with Nika BioTechnology, Inc. and the acquisition and subsequent cancellation of the acquisition of Nika Pharmaceuticals, Ltd.
• Nika Europe, Ltd., a subsidiary, is in the process of establishing a pharmaceutical factory, with a vial production line expected to be installed by the end of Q4 2024.
• The company has entered into a production agreement with Nika Europe, Ltd. for the production of ITV-1, with Nika Pharmaceuticals, Inc. expecting a profit of around $1,120 per set.
• The company's financial statements have been prepared assuming it will continue as a going concern, but there is substantial doubt about its ability to do so due to accumulated deficits and lack of revenue.

Sentiment

Score: 3

Explanation: The document reveals significant financial losses, a weak cash position, and material weaknesses in internal controls. While there are some positive developments, such as the production agreement and factory development, the overall sentiment is negative due to the company's financial instability and operational challenges.

Positives

• The company has secured a production agreement with Nika Europe, Ltd. for ITV-1, which is expected to generate a profit of $1,120 per set.
• The company has acquired four technologies for generic drugs and dietary supplements, expanding its product portfolio.
• The company is establishing a pharmaceutical factory through its subsidiary Nika Europe, Ltd., which will provide manufacturing capabilities.
• The company has increased its ownership in Nika Europe, Ltd. to 80% through a merger.

Negatives

• The company has incurred a net loss of $8,367 for the quarter and $83,339 for the nine-month period.
• The company's cash balance has significantly decreased to $1,386.
• The company has an accumulated deficit of $8,915,159.
• The company's disclosure controls and procedures were deemed not effective for the quarter ended September 30, 2024.
• The company has identified material weaknesses in its internal controls, including a lack of an audit committee and separation of duties.
• The company cancelled the acquisition of Nika Pharmaceuticals, Ltd. after initially acquiring it, which resulted in the loss of the factory building and land.

Risks

• The company has a substantial accumulated deficit and has generated no revenue to date, raising doubts about its ability to continue as a going concern.
• The company's reliance on related party loans for funding poses a risk.
• The company's internal controls are not effective, which could lead to errors in financial reporting.
• The company's complex restructuring activities and changes in subsidiaries could create operational challenges.
• The company's ability to successfully establish its pharmaceutical manufacturing capabilities is uncertain.
• The company's dependence on a single production agreement with Nika Europe, Ltd. for ITV-1 creates a risk if that agreement is not successful.

Future Outlook

The company is focused on establishing its pharmaceutical manufacturing capabilities through its subsidiary Nika Europe, Ltd. and expects to generate revenue from the production of ITV-1. However, the company's ability to continue as a going concern is uncertain.

Management Comments

• The company's CEO and CFO have certified that the report does not contain any untrue statement of a material fact and fairly presents the financial condition and results of operations.
• Management has acknowledged the material weaknesses in internal controls and is working to address them.

Industry Context

The pharmaceutical industry is highly competitive and requires significant capital investment. Nika Pharmaceuticals is attempting to establish itself in this industry through acquisitions, mergers, and the development of manufacturing capabilities. The company's focus on generic drugs and dietary supplements aligns with current market trends, but it faces challenges in securing funding and establishing a strong market presence.

Comparison to Industry Standards

• Nika Pharmaceuticals is a small, early-stage company with limited revenue and significant losses, which is not uncommon for companies in the development phase of the pharmaceutical industry.
• Compared to established pharmaceutical companies like Pfizer or Johnson & Johnson, Nika's financial metrics are significantly weaker, reflecting its early stage of development.
• The company's focus on generic drugs and dietary supplements is similar to other smaller pharmaceutical companies, but its lack of revenue and significant losses are a concern.
• The company's efforts to establish a manufacturing facility are similar to other companies in the industry, but its financial constraints and reliance on related party loans are a significant risk.
• The company's internal control weaknesses are a concern and need to be addressed to meet industry standards for financial reporting.

Management Changes

Corporate Governance

Related Party Transactions

• Dimitar Slavchev Savov, CEO, advanced the Company $103,419 and $83,565 during the periods ended September 30, 2024 and December 31, 2023, respectively.
• Nika Pharmaceuticals, Ltd. wire transferred $5,000 to Nika Pharmaceuticals Inc. on July 9, 2024.
• The company issued 8,000,000 shares of Preferred stock to be issued in the name of Dimitar Slavchev Savov for the Exclusive Rights Agreement with VITAL.
• The company issued 2,000,000 shares of Preferred stock to be issued in the name of Dimitar Slavchev Savov for the Exclusive Rights Agreement with MICAR.
• Dimitar Savov paid $42,491 for four technologies acquired by Nika Europe, Ltd.
• Dimitar Savov paid the initial down payment of $191,534 for the vial production line equipment.
• Nika Pharmaceuticals, Ltd. made a non-monetary in-kind contribution of a production building and land to the capital of Nika Europe, Ltd.

Stakeholder Impact

• Shareholders are impacted by the company's net losses and the uncertainty about its ability to continue as a going concern.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and suppliers may be impacted by the company's ability to establish its manufacturing capabilities and deliver products.
• Creditors are at risk due to the company's significant liabilities and limited cash reserves.

Next Steps

• The company needs to complete the installation of the vial production line in its Bulgarian factory by the end of Q4 2024.
• The company needs to address the material weaknesses in its internal controls.
• The company needs to secure additional funding to support its operations and growth.
• The company needs to finalize the accounting for the common control merger.
• The company needs to begin production of ITV-1 under the agreement with Nika Europe, Ltd.

Key Dates

Keywords

Pharmaceuticals, Manufacturing, Merger, Biotechnology, Financial Results, Net Loss, Going Concern, Related Party Transactions, Internal Controls, Nika Europe, ITV-1